BeOne reported $1.89 billion of Q3 revenue and $384.7 million of GAAP net income. Its higher full-year ranges are guidance, not completed results.
BeOne Medicines reported unaudited third-quarter revenue of $1.890 billion, up 34% from a year earlier. Net product revenue was $1.855 billion and other revenue was $34.8 million.
GAAP net income was $384.7 million, compared with $124.8 million a year earlier. Diluted GAAP earnings per ADS were $3.28, while non-GAAP diluted earnings per ADS were $4.59. These are not interchangeable measures.
The company raised full-year 2026 total-revenue guidance to $6.9 billion–$7.0 billion from $6.6 billion–$6.8 billion. That range reflects management estimates and assumptions for the rest of the year, not revenue already recorded.
| Measure | Reported figure | Qualification |
|---|---|---|
| Q3 revenue | $1.890bn | +34% year on year; unaudited |
| GAAP net income | $384.7m | Reported accounting result |
| GAAP / non-GAAP diluted ADS EPS | $3.28 / $4.59 | Different measurement bases |
| 2026 revenue guidance | $6.9bn–$7.0bn | Forward-looking company range |
How to read the figures
The source record should be read with its reporting scope and period intact. A reported accounting measure, a constant-currency comparison and management guidance answer different questions; none on its own establishes a later market price, customer outcome or investment return.
What to watch
The useful next check is a later official filing or release that confirms whether guidance, targets or accounting comparisons changed. CapKet will not treat a target, estimate or management explanation as a completed financial outcome without separate primary evidence.
Primary sources: BeOne Medicines official release or filing and related official filing, checked 2026-11-05T19:35:21.193850+00:00.
CapKet disclosure: Source-backed news, not investment advice. AI-assisted review is not independent human approval.